Reference health
PSMA-Targeted Mesoporous Silica Nanoparticles for Selective Intracellular Delivery of Docetaxel in Prostate Cancer Cells
61/61 checkable references clean · checked 2026-07-22
Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.
3 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
The 61 checked references that resolve
resolves10.2147/CMAR.S49321
Benefit risk assessment and update on the use of docetaxel in the management of breast cancer
resolves10.1038/sj.bjc.6600685
Docetaxel induction therapy in locally advanced squamous cell carcinoma of the head and neck
resolves10.1016/S0305-7372(03)00097-5
Mode of action of docetaxel – a basis for combination with novel anticancer agents
resolves10.1023/A:1025436307913
The mechanism of action of docetaxel (Taxotere®) in xenograft models is not limited to bcl-2 phosphorylation
resolves10.1016/j.ijpharm.2013.12.027
A novel aqueous parenteral formulation of docetaxel using prodrugs
resolves10.2147/IJN.S143977
Multifunctional gold nanorods and docetaxel-encapsulated liposomes for combined thermo- and chemotherapy
resolves10.2147/IJN.S139167
Docetaxel-titanate nanotubes enhance radiosensitivity in an androgen-independent prostate cancer model
resolves10.2147/IJN.S124995
Synthesis and in vitro studies of PLGA-DTX nanoconjugate as potential drug delivery vehicle for oral cancer
resolves10.2147/IJN.S40766
Magnetic nanoparticles of Fe3O4 enhance docetaxel-induced prostate cancer cell death
resolves10.2147/OTT.S113815
Mesoporous silica nanoparticles functionalized with folic acid/methionine for active targeted delivery of docetaxel
resolves10.1186/s12951-015-0068-6
Lactosaminated mesoporous silica nanoparticles for asialoglycoprotein receptor targeted anticancer drug delivery
resolves10.1016/j.jconrel.2016.12.023
Safe approaches for camptothecin delivery: Structural analogues and nanomedicines
resolves10.1007/s11095-016-1958-5
Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date
resolves10.1111/bph.13576
The therapeutic and diagnostic potential of the prostate specific membrane antigen/glutamate carboxypeptidase II (PSMA/GCPII) in cancer and neurological disease
resolves10.1002/jcb.10661
Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer
resolves10.1002/ijc.11402
Expression of prostate specific membrane antigen and three alternatively spliced variants of PSMA in prostate cancer patients
resolves10.1002/pros.10319
Comparative analysis of prostate‐specific membrane antigen (PSMA) versus a prostate‐specific membrane antigen‐like gene
resolves10.1073/pnas.0601755103
Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy
<i>in vivo</i>
resolves10.1016/j.colsurfb.2015.05.030
LFC131 peptide-conjugated polymeric nanoparticles for the effective delivery of docetaxel in CXCR4 overexpressed lung cancer cells
resolves10.1007/s11095-016-1945-x
Targeting Nanomedicines to Prostate Cancer: Evaluation of Specificity of Ligands to Two Different Receptors In Vivo
resolves10.1016/j.nano.2016.08.017
Anti-CD24 nano-targeted delivery of docetaxel for the treatment of prostate cancer
resolves10.1016/j.colsurfb.2016.03.071
PSMA targeted docetaxel-loaded superparamagnetic iron oxide nanoparticles for prostate cancer
resolves10.1158/1078-0432.CCR-15-2548
Phase I Study of PSMA-Targeted Docetaxel-Containing Nanoparticle BIND-014 in Patients with Advanced Solid Tumors
resolves10.1021/acsomega.6b00126
Prostate-Specific Membrane Antigen Targeted Polymersomes for Delivering Mocetinostat and Docetaxel to Prostate Cancer Cell Spheroids
resolves10.1021/acsnano.8b00940
Prostate-Specific Membrane Antigen Targeted Gold Nanoparticles for Theranostics of Prostate Cancer
resolves10.1002/mabi.201600421
Co‐Delivery of Docetaxel and p44/42 MAPK siRNA Using PSMA Antibody‐Conjugated BSA‐PEI Layer‐by‐Layer Nanoparticles for Prostate Cancer Target Therapy
resolves10.2174/2211555204666151003003204
In vitro Evaluation of Gadolinium-Silica Mesoporous Nanoparticles- Monoclonal Antibody: Potential Nanoprobe for Prostate Cancer Cell Imaging
resolves10.1016/j.bbrc.2018.03.124
Novel gadopentetic acid-doped silica nanoparticles conjugated with YPSMA-1 targeting prostate cancer for MR imaging: an in vitro study
resolves10.1002/cmdc.201300549
Development and Screening of a Series of Antibody‐Conjugated and Silica‐Coated Iron Oxide Nanoparticles for Targeting the Prostate‐Specific Membrane Antigen
resolves10.1021/cm990661z
Dilute Solution Routes to Various Controllable Morphologies of MCM-41 Silica with a Basic Medium
resolves10.1016/j.apsusc.2015.01.204
CD44-engineered mesoporous silica nanoparticles for overcoming multidrug resistance in breast cancer
resolves10.1021/jp2047147
Measurement of Uptake and Release Capacities of Mesoporous Silica Nanoparticles Enabled by Nanovalve Gates
resolves10.1155/2013/924362
Different Effects of the Immunomodulatory Drug GMDP Immobilized onto Aminopropyl Modified and Unmodified Mesoporous Silica Nanoparticles upon Peritoneal Macrophages of Women with Endometriosis
resolves10.1371/journal.pone.0108586
Efficient Preparation of Enantiopure D-Phenylalanine through Asymmetric Resolution Using Immobilized Phenylalanine Ammonia-Lyase from Rhodotorula glutinis JN-1 in a Recirculating Packed-Bed Reactor
resolves10.1039/C7AN01424D
The influence of covalent immobilization conditions on antibody accessibility on nanoparticles
resolves10.1016/j.nano.2010.11.004
Comparing cellular uptake and cytotoxicity of targeted drug carriers in cancer cell lines with different drug resistance mechanisms
resolves10.1016/j.bmcl.2017.07.041
Docetaxel prodrug self-assembled nanosystem: Synthesis, formulation and cytotoxicity
resolves10.3109/10717544.2015.1069423
Targeted nanomedicine for prostate cancer therapy: docetaxel and curcumin co-encapsulated lipid–polymer hybrid nanoparticles for the enhanced anti-tumor activity<i>in vitro</i>and<i>in vivo</i>
resolves10.3389/fphar.2017.00249
Docetaxel-Loaded Nanoparticles Assembled from β-Cyclodextrin/Calixarene Giant Surfactants: Physicochemical Properties and Cytotoxic Effect in Prostate Cancer and Glioblastoma Cells
resolves10.1002/pros.21454
Prostate cancer targeting motifs: Expression of α<sub>ν</sub>β<sub>3</sub>, neurotensin receptor 1, prostate specific membrane antigen, and prostate stem cell antigen in human prostate cancer cell lines and xenografts
resolves10.1016/j.abb.2004.12.003
Expression of prostate specific membrane antigen in androgen-independent prostate cancer cell line PC-3
resolves10.1158/0008-5472.727.65.3
Novel Role of Prostate-Specific Membrane Antigen in Suppressing Prostate Cancer Invasiveness
resolves10.1002/smll.200901789
Mesoporous Silica Nanoparticles for Intracellular Controlled Drug Delivery
resolves10.1007/s12030-008-9003-3
Mesoporous Silica Nanoparticles for Cancer Therapy: Energy-Dependent Cellular Uptake and Delivery of Paclitaxel to Cancer Cells
resolves10.1021/ja0645943
Effect of Surface Functionalization of MCM-41-Type Mesoporous Silica Nanoparticles on the Endocytosis by Human Cancer Cells
resolves10.1021/bc200284b
Synthetic Modification of Carboxymethylcellulose and Use Thereof to Prepare a Nanoparticle Forming Conjugate of Docetaxel for Enhanced Cytotoxicity against Cancer Cells
resolves10.2147/IJN.S93409
Quantitative [Fe]MRI of PSMA-targeted SPIONs specifically discriminates among prostate tumor cell types based on their PSMA expression levels
resolves10.1021/mp5002813
Pharmacokinetics of an Injectable Modified-Release 2-Hydroxyflutamide Formulation in the Human Prostate Gland Using a Semiphysiologically Based Biopharmaceutical Model
resolves10.1016/j.ijpharm.2013.04.020
Synthesis, characterization and antitumor evaluation of CMCS–DTX conjugates as novel delivery platform for docetaxel
resolves10.1021/jp962000k
Adsorption Study of Surface and Structural Properties of MCM-41 Materials of Different Pore Sizes
The 3 references without a DOI — listed, not checked
no DOI — not checkedref3/cit3
no DOI — not checkedref58/cit58
no DOI — not checkedAssay Guidance Manual
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-07-22 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.1021/acsomega.8b02909"><img src="https://citestamp.com/citestamped/10.1021/acsomega.8b02909/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[](https://citestamp.com/citestamped/10.1021/acsomega.8b02909)